In contrast, within the AML microenvironment, HOXA5 appears to sustain leukemogenesis through distinct mechanisms, principally metabolic reprogramming involving cholesterol biosynthesis and alterations in ECM-receptor interactions, as evidenced by our functional genomics and knockdown experiments. This evidence concerns the gene HOXA5 and acute myeloid leukemia.